Recruiting Clinical Trials

Displaying 111 - 120 of 242 result(s)
Study Title Condition Phase Location
Phase I, Open Label, Study of B-cell Maturation Antigen (BCMA)-Directed CAR-T Cells in Adult Patients With Relapsed and/or Refractory Multiple Myeloma Multiple Myeloma Phase 1
  • Country: 
    United States
A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET Gastro-enteropancreatic Neuroendocrine Tumor Phase 3
  • Country: 
    United States
  • Country: 
    Canada
  • Country: 
    France
  • Country: 
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositi ... Triple Negative Breast Neoplasms Phase 3
  • Country: 
    United States
  • Country: 
    Argentina
  • Country: 
    Australia
  • Country: 
A Phase I/Ib, Open-label, Multi-center, Study of DKY709 as a Single Agent and in Combination With PDR001 in Patients With Advanced Solid Tumors Carcinoma, Non-Small-Cell Lung, Melanoma, Nasopharyngeal Carcinoma, Microsatellite Stable Colorectal Cancer, Triple Negative Breast Cancer Phase 1
  • Country: 
    United States
  • Country: 
    Germany
  • Country: 
    Hong Kong
  • Country: 
A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy B-Cell Acute Lymphoblastic Leukemia Phase 2
  • Country: 
    United States
  • Country: 
    Belgium
  • Country: 
    Canada
  • Country: 
A Randomized, Participant and Investigator Blinded, Sponsor Open-label, Placebo-controlled, Single Dose Study to Investigate the Safety and Tolerability of XXB750 in Heart Failure Participants With Reduced Ejection Fraction (HFrEF) Heart Failure With Reduced Ejection Fraction (HFrEF) Phase 1
  • Country: 
    United States
EPIK-O: A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no ... Ovarian Cancer Phase 3
  • Country: 
    United States
  • Country: 
    Argentina
  • Country: 
    Australia
  • Country: 
A Randomized, Open-label, Two Arm, Parallel Group, Proof-of-concept Clinical Trial to Investigate the Efficacy and Safety of LNP023 Compared With Rituximab in the Treatment of Subjects With Idiopathic Membranous Nephropathy Glomerulonephritis, Membranous Phase 2
  • Country: 
    United States
  • Country: 
    Argentina
  • Country: 
    China
  • Country: 
A Phase Ib/II Open Label Dose Confirmation, Proof of Concept Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Unfit Adult AML Participants Who Responded Sub-optimally to First-line Venetoclax Plus Azacitidine Treatment and in Pa ... Acute Myeloid Leukemia Phase 1, Phase 2
  • Country: 
    Hungary
  • Country: 
    Malaysia
EPIK-B5: A Phase III, Randomized, Double-blind, Placebo-controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With HR-positive, HER2-negative Advanced Breast Cancer With a PIK3CA Mutation, Who Progressed on or ... Breast Cancer Phase 3
  • Country: 
    Belgium
  • Country: 
    Bulgaria
  • Country: 
    Czech Republic
  • Country: